Showing results (481-490 of 513) with videos related to
Sort By:
Pageof 52
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Proceedings of the National Academy of Sciences of the United States of America|August 22, 2012
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Heidi Greulich, Bethany Kaplan, Philipp Mertins, et al.Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabZofia Piotrowska, Antonio Passaro, Danny Nguyen, et al.Cancer Medicine|January 17, 2023
Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancersJi Eun Kim, Hyemin Kim, Binnari Kim, et al.The Oncologist|August 26, 2015
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck CancerKeun-Wook Lee, Youngil Koh, Sung-Bae Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2023
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)Sehhoon Park, Tae Min Kim, Ji-Youn Han, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckHan Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.Journal for Immunotherapy of Cancer|February 14, 2024
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer typesJeanne Shen, Yoon-La Choi, Taebum Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2022
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung CancerSehhoon Park, Chan-Young Ock, Hyojin Kim, et al.Pageof 52